Engineering ERα degraders with pleiotropic ubiquitin ligase ligands maximizes therapeutic efficacy by co-opting distinct effector ligases
Proximity-inducing compounds that modulate target protein homeostasis are an emerging therapeutic strategy [1]. While the inherent complexity of these bifunctional compounds poses challenges for rational design and bioavailability, their composition also provides opportunities to co-opt specific cellular proteins to maximize therapeutic impact. Here, we systematically evaluate the cellular efficacy, biophysical mechanisms, and therapeutic benefits of a series of bifunctional degrader compounds, that are all engineered with the Estrogen Receptor-alpha (ER)-inhibitor endoxifen linked to different bioactive ubiquitin ligase ligands. Bifunctional ER degraders that incorporate CRL4-CRBN-binding ligands promoted the most potent ER degradation, whereas those incorporating either CRL2-VHL- or IAP-binding ligands maximized the depth of ER degradation. Notably, ER degraders containing pan-IAP antagonist ligands significantly decreased the proliferation of ER-dependent cells relative to clinical-stage ER-degraders, including the SERDs fulvestrant and GDC-9545 and the bifunctional degrader ARV-471. Mechanistic studies revealed that pan-IAP antagonist-based ER degraders uniquely promote TNF-dependent cell death, unlike the clinical-stage comparators. Remarkably, the pan-IAP antagonist-ER-degraders co-opt distinct effector ligases to achieve dual therapeutic effects: they harness XIAP within tumor cells to promote ER degradation, and activate cIAP1/2 within tumor and immune cells to induce TNF that drives tumor cell death. Our studies demonstrate a broader concept that co-opting the discrete functions of a selected set of cellular effectors, while simultaneously modulating therapeutic target protein homeostasis, are dual strategies that can be leveraged to maximize the efficacy of induced proximity therapeutics.